SEARCH

SEARCH BY CITATION

References

  • 1
    Hardeland R & Fuhrberg B (1996) Ubiquitous melatonin. Presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol 2, 2545.
  • 2
    Reiter RJ & Tan DX (2002) Melatonin: an antioxidant in edible plants. Ann N Y Acad Sci 957, 341344.
  • 3
    Hardeland R & Poeggeler B (2003) Non-vertebrate melatonin. J Pineal Res 34, 233241.
  • 4
    Chen G, Huo Y, Tan DX, Liang Z, Zhang W & Zhang Y (2003) Melatonin in Chinese medicinal herbs. Life Sci 73, 1926.
  • 5
    Hardeland R & Pandi-Perumal SR (2005) Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2, 22.
  • 6
    Claustrat B, Brun J & Chazot G (2005) The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9, 1124.
  • 7
    Cardinali DP & Rosner JM (1971) Metabolism of serotonin by the rat retina ‘in vitro’. J Neurochem 18, 17691770.
  • 8
    Tosini G & Menaker M (1998) The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration. Brain Res 789, 221228.
  • 9
    Liu C, Fukuhara C, Wessel JH III, Iuvone PM & Tosini G (2004) Localization of Aa-nat mRNA in the rat retina by fluorescence in situ hybridization and laser capture microdissection. Cell Tissue Res 315, 197201.
  • 10
    Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M & Maestroni JM (2000) Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28, 193202.
  • 11
    Champier J, Claustrat B, Besancon R, Eymin C, Killer C, Jouvet A, Chamba G & Fevre-Montange M (1997) Evidence for tryptophan hydroxylase and hydroxy-indol-O-methyl- transferase mRNAs in human blood platelets. Life Sci 60, 21912197.
  • 12
    Bubenik GA (2002) Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47, 23362348.
  • 13
    Slominski A, Wortsman J & Tobin DJ (2005) The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J 19, 176194.
  • 14
    Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, Slominski RM & Tobin DJ (2005) On the role of melatonin in skin physiology and pathology. Endocrine 27, 137148.
  • 15
    Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ & Guerrero JM (2004) Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18, 537539.
  • 16
    Karasek M, Reiter RJ, Cardinali DP & Pawlikowski M (2002) Future of melatonin as a therapeutic agent. Neuroendocrinol Lett 23 (Suppl. 1), 118121.
  • 17
    Pandi-Perumal SR, Zisapel N, Srinivasan V & Cardinali DP (2005) Melatonin and sleep in aging population. Exp Gerontol 40, 911925.
  • 18
    Srinivasan V, Pandi-Perumal SR, Maestroni GJM, Esquifino AI, Hardeland R & Cardinali DP (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7, 293318.
  • 19
    Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino AI, Pandi-Perumal SR & Miller SC (2005) Melatonin, immune function and aging. Immun Ageing 2, 17.
  • 20
    Kolar J & Machackova I (2005) Melatonin in higher plants: occurrence and possible functions. J Pineal Res 39, 333341.
  • 21
    Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T & Reiter RJ (1995) Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 35, 627634.
  • 22
    Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM & Reiter RJ (2003) Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34, 7578.
  • 23
    Axelrod J (1974) The pineal gland: a neurochemical transducer. Science 184, 13411348.
  • 24
    Moore RY (1997) Circadian rhythms: basic neurobiology and clinical applications. Annu Rev Med 48, 253266.
  • 25
    Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E & Rollag MD (2001) Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21, 64056412.
  • 26
    Berson DM, Dunn FA & Takao M (2002) Phototransduction by retinal ganglion cells that set the circadian clock. Science 295, 10701073.
  • 27
    Klein DC (2004) The 2004 Aschoff/Pittendrigh lecture: Theory of the origin of the pineal gland – a tale of conflict and resolution. J Biol Rhythms 19, 264279.
  • 28
    Gerdin MJ, Masana MI, Rivera-Bermudez MA, Hudson RL, Earnest DJ, Gillette MU & Dubocovich ML (2004) Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 18, 16461656.
  • 29
    Karolczak M, Korf HW & Stehle JH (2005) The rhythm and blues of gene expression in the rodent pineal gland. Endocrine 27, 89100.
  • 30
    Hardeland R, Pandi-Perumal SR & Cardinali DP (2006) Melatonin. Int J Biochem Cell Biol 38, 313316.
  • 31
    Tricoire H, Moller M, Chemineau P & Malpaux B (2003) Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 61, 311321.
  • 32
    Cardinali DP & Pevet P (1998) Basic aspects of melatonin action. Sleep Med Rev 2, 175190.
  • 33
    Macchi MM & Bruce JN (2004) Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 25, 177195.
  • 34
    Griefahn B, Brode P, Remer T & Blaszkewicz M (2003) Excretion of 6-hydroxymelatonin sulfate (6-OHMS) in siblings during childhood and adolescence. Neuroendocrinology 78, 241243.
  • 35
    Ma X, Idle JR, Krausz KW & Gonzalez FJ (2005) Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 33, 489494.
  • 36
    Hardeland R, Poeggeler B, Behrmann G & Fuhrberg B (1996) Enzymatic and non-enzymatic metabolism of methoxyindoles. In Metabolism and Cellular Dynamics of Indoles (HardelandR, ed.), pp. 622. University of Goettingen, Goettingen.
  • 37
    Hardeland R, Reiter RJ, Poeggeler B & Tan DX (1993) The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17, 347357.
  • 38
    Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, Vijayalaxmi & Shepherd AM (1998) A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253, 614620.
  • 39
    Hirata F, Hayaishi O, Tokuyama T & Seno S (1974) In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 249, 13111313.
  • 40
    Tan DX, Reiter RJ, Manchester LC, Yan MT, El Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M & Hardeland R (2002) Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2, 181197.
  • 41
    Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC, Kohen R, Shohami E, Huo YS, Hardeland R & Reiter RJ (2001) N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 15, 22942296.
  • 42
    Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX, Poeggeler B, Antolin I, Zsizsik BK, Reiter RJ & Hardeland R (2003) Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 8, 205213.
  • 43
    Kelly RW, Amato F & Seamark RF (1984) N-acetyl-5-methoxy kynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun 121, 372379.
  • 44
    Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C & Reiter RJ (2005) Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 165, 139149.
  • 45
    Ferry G, Ubeaud C, Lambert PH, Bertin S, Coge F, Chomarat P, Delagrange P, Serkiz B, Bouchet JP, Truscott RJ et al. (2005) Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan. Investigation on both indoleamine-2,3-dioxygenase and myeloperoxidase. Biochem J 388, 205215.
  • 46
    Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S & Hardeland R (2002) Melatonin's unique radical scavenging properties – roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 33, 2030.
  • 47
    Tan DX, Hardeland R, Manchester LC, Poeggeler B, Lopez-Burillo S, Mayo JC, Sainz RM & Reiter RJ (2003) Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res 34, 249259.
  • 48
    Lopez-Burillo S, Tan DX, Rodriguez-Gallego V, Manchester LC, Mayo JC, Sainz RM & Reiter RJ (2003) Melatonin and its derivatives cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine and 6-methoxymelatonin reduce oxidative DNA damage induced by Fenton reagents. J Pineal Res 34, 178184.
  • 49
    Hardeland R (2005) Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 27, 119130.
  • 50
    Rozov SV, Filatova EV, Orlov AA, Volkova AV, Zhloba AR, Blashko EL & Pozdeyev NV (2003) N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 35, 245250.
  • 51
    Hardeland R, Poeggeler B, Niebergall R & Zelosko V (2003) Oxidation of melatonin by carbonate radicals and chemiluminescence emitted during pyrrole ring cleavage. J Pineal Res 34, 1725.
  • 52
    Hardeland R (1997) Melatonin: multiple functions in signaling and protection. In Skin Cancer and UV Radiation (AltmeyerP, HoffmannK & StuckerM, eds), pp. 186198. Springer, Berlin – Heidelberg.
  • 53
    Hardeland R, Coto-Montes A & Poeggeler B (2003) Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol Int 20, 921962.
  • 54
    Wurtman RJ & Zhdanova I (1995) Improvement of sleep quality by melatonin. Lancet 346, 1491.
  • 55
    Lavie P (1997) Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 12, 657665.
  • 56
    Zisapel N (2001) Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 15, 311328.
  • 57
    Doolen S, Krause DN, Dubocovich ML & Duckles SP (1998) Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 345, 6769.
  • 58
    Scheer FA, Van Montfrans GA, Van Someren EJ, Mairuhu G & Buijs RM (2004) Daily night-time melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43, 192197.
  • 59
    Guerrero JM & Reiter RJ (2002) Melatonin-immune system relationships. Curr Top Med Chem 2, 167179.
  • 60
    Esquifino AI, Pandi-Perumal SR & Cardinali DP (2004) Circadian organization of the immune response: a role for melatonin. Clin Appl Immunol Rev 4, 423433.
  • 61
    Carrillo-Vico A, Guerrero JM, Lardone PJ & Reiter RJ (2005) A review of the multiple actions of melatonin on the immune system. Endocrine 27, 189200.
  • 62
    Armstrong SM (1989) Melatonin and circadian control in mammals. Experientia 45, 932938.
  • 63
    Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC & Chaurasia SS (2005) Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res 24, 433456.
  • 64
    Reiter RJ, Tan DX & Maldonado MD (2005) Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 39, 215216.
  • 65
    Blask DE, Dauchy RT & Sauer LA (2005) Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27, 179188.
  • 66
    Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA & Mautalen CA (2003) Melatonin effects on bone: Experimental facts and clinical perspectives. J Pineal Res 34, 8187.
  • 67
    Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC & Barlow-Walden LR (1994) Melatonin – a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 738, 419420.
  • 68
    Matuszak Z, Reszka K & Chignell CF (1997) Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic Biol Med 23, 367372.
  • 69
    Stasica P, Ulanski P & Rosiak JM (1998) Melatonin as a hydroxyl radical scavenger. J Pineal Res 25, 6566.
  • 70
    Reiter RJ, Tan DX, Manchester LC & Qi W (2001) Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 34, 237256.
  • 71
    Mahal HS, Sharma HS & Mukherjee T (1999) Antioxidant properties of melatonin: a pulse radiolysis study. Free Rad Biol Med 26, 557565.
  • 72
    Zhang H, Squadrito GL & Pryor WA (1998) The reaction of melatonin with peroxynitrite: formation of melatonin radical cation and absence of stable nitrated products. Biochem Biophys Res Commun 251, 8387.
  • 73
    Noda Y, Mori A, Liburdy R & Packer L (1999) Melatonin and its precursors scavenge nitric oxide. J Pineal Res 27, 159163.
  • 74
    Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL & Szabo C (1997) Melatonin is a scavenger of peroxynitrite. Life Sci 60, L169L174.
  • 75
    Blanchard B, Pompon D & Ducrocq C (2000) Nitrosation of melatonin by nitric oxide and peroxynitrite. J Pineal Res 29, 184192.
  • 76
    Burkhardt S, Reiter RJ, Tan DX, Hardeland R, Cabrera J & Karbownik M (2001) DNA oxidatively damaged by chromium (III) and H2O2 is protected by the antioxidants melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 33, 775783.
  • 77
    Than NN, Heer C, Laatsch H & Hardeland R (2006) Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products. Redox Rep 11, 1524.
  • 78
    Guenther AL, Schmidt SI, Laatsch H, Fotso S, Ness H, Ressmeyer AR, Poeggeler B & Hardeland R (2005) Reactions of the melatonin metabolite AMK (N-acetyl-5-methoxykynuramine) with reactive nitrogen species: Formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J Pineal Res 39, 251260.
  • 79
    Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD & Poeggeler B (1995) Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 26, 497502.
  • 80
    Pablos MI, Reiter RJ, Ortiz GG, Guerrero JM, Agapito MT, Chuang JI & Sewerynek E (1998) Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 32, 6975.
  • 81
    Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S, Honma K & Kondo T (1999) Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 27, 838847.
  • 82
    Reiter RJ, Guerrero JM, Garcia JJ & Acuna-Castroviejo D (1998) Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann N Y Acad Sci 854, 410424.
  • 83
    Mayo JC, Sainz RM, Antoli I, Herrera F, Martin V & Rodriguez C (2002) Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 59, 17061713.
  • 84
    Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V & Reiter RJ (2004) Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36, 19.
  • 85
    Reiter RJ (1998) Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56, 359384.
  • 86
    Gomez M, Esparza JL, Nogues MR, Giralt M, Cabre M & Domingo JL (2005) Pro-oxidant activity of aluminum in the rat hippocampus: gene expression of antioxidant enzymes after melatonin administration. Free Radic Biol Med 38, 104111.
  • 87
    Pozo D, Reiter RJ, Calvo JR & Guerrero JM (1994) Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci 55, L455L460.
  • 88
    Bettahi I, Pozo D, Osuna C, Reiter RJ, Acuna-Castroviejo D & Guerrero JM (1996) Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res 20, 205210.
  • 89
    Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL & Szabo C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF kappa B activation. FASEB J 12, 685693.
  • 90
    Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V & Allescher HD (2002) Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 33, 101108.
  • 91
    Uz T & Manev H (1998) Circadian expression of pineal 5-lipoxygenase mRNA. Neuroreport 9, 783786.
  • 92
    Manev H, Uz T & Qu T (1998) Early upregulation of hippocampal 5-lipoxygenase following systemic administration of kainate to rats. Rest Neurol Neurosci 12, 8185.
  • 93
    Zhang H, Akbar M & Kim HY (1999) Melatonin: an endogenous negative modulator of 12-lipoxygenation in the rat pineal gland. Biochem J 344, 487493.
  • 94
    Reppert SM, Weaver DR & Ebisawa T (1994) Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13, 11771185.
  • 95
    Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA & Gusella JF (1995) Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 92, 87348738.
  • 96
    Dubocovich ML, Cardinali DP, Delagrange P, Krause DN, Strosberg D, Sugden D & Yocca FD (2000) Melatonin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn. (IUPHAR, ed.), pp. 271277. IUPHAR Media, London.
  • 97
    Dubocovich ML & Markowska M (2005) Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27, 101110.
  • 98
    Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E & Boutin JA (2000) Identification of the melatonin binding site MT3 as the quinone reductase 2. J Biol Chem 275, 3131131317.
  • 99
    Foster CE, Bianchet MA, Talalay P, Faig M & Amzel LM (2000) Structures of mammalian cytosolic quinone reductases. Free Radic Biol Med 29, 241245.
  • 100
    Benitez-King G (2006) Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 40, 19.
  • 101
    Wiesenberg I, Missbach M, Kahlen JP, Schrader M & Carlberg C (1995) Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 23, 327333.
  • 102
    Carlberg C (2000) Gene regulation by melatonin. Ann N Y Acad Sci 917, 387396.
  • 103
    Andrabi SA, Sayeed I, Siemen D, Wolf G & Horn TF (2004) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 18, 869871.
  • 104
    Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J & Pappolla MA (1999) Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 274, 2193721942.
  • 105
    Genova ML, Pich MM, Bernacchia A, Bianchi C, Biondi A, Bovina C, Falasca AI, Formiggini G, Castelli GP & Lenaz G (2004) The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci 1011, 86100.
  • 106
    Martin M, Macias M, Escames G, Reiter RJ, Agapito MT, Ortiz GG & Acuna-Castroviejo D (2000) Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 28, 242248.
  • 107
    Martin M, Macias M, Leon J, Escames G, Khaldy H & Acuna-Castroviejo D (2002) Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 34, 348357.
  • 108
    Acuña-Castroviejo D, Escames G, Leon J, Carazo A & Khaldy H (2003) Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 527, 549557.
  • 109
    Leon J, Acuna-Castroviejo D, Escames G, Tan DX & Reiter RJ (2005) Melatonin mitigates mitochondrial malfunction. J Pineal Res 38, 19.
  • 110
    Cardinali DP (2005) Melatonin as a prototype of chronobiotic-cytoprotective drugs. Physiol Mini-Rev 1, 2534.
  • 111
    Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340, 19701980.
  • 112
    Srinivasan V (2002) Melatonin oxidative stress and neurodegenerative diseases. Indian J Exp Biol 40, 668679.
  • 113
    Pappolla MA, Chyan Y, Poeggeler B, Frangione B, Wilson G, Ghiso J & Reiter RJ (2000) An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for Alzheimer's disease. J Neural Transm 107, 203231.
  • 114
    Kaplan DR & Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10, 381391.
  • 115
    Takuma K, Yan SS, Stern DM & Yamada K (2005) Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 97, 312316.
  • 116
    Maurizi CP (2001) Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med Hypoth 57, 156160.
  • 117
    Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R & Cardinali DP (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7, 293318.
  • 118
    Matsubara E, Bryant-Thomas T, Pacheco QJ, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G et al. (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85, 11011108.
  • 119
    Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C & Zhang JT (2004) Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 37, 129136.
  • 120
    Feng Z, Qin C, Chang Y & Zhang JT (2006) Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 40, 101109.
  • 121
    Poeggeler B, Miravalle L, Zagorski MG, Wisniewski T, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B et al. (2001) Melatonin reverses the profibrillogenic activity of apolipoprotein e4 on the Alzheimer amyloid abeta Peptide. Biochemistry 40, 1499515001.
  • 122
    Brusco LI, Marquez M & Cardinali DP (1998) Monozygotic twins with Alzheimer's disease treated with melatonin: Case report. J Pineal Res 25, 260263.
  • 123
    Brusco LI, Marquez M & Cardinali DP (1998) Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 19, 111115.
  • 124
    Cohen-Mansfield J, Garfinkel D & Lipson S (2000) Melatonin for treatment of sundowning in elderly persons with demen. Arch Gerontol Geriatr 31, 6576.
  • 125
    Mishima K, Okawa M, Hozumi S & Hishikawa Y (2000) Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 17, 419432.
  • 126
    Cardinali DP, Brusco LI, Liberczuk C & Furio AM (2002) The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 23 (Suppl. 1), 2023.
  • 127
    Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y & Endo S (2003) Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70, 334341.
  • 128
    Mahlberg R, Kunz D, Sutej I, Kuhl KP & Hellweg R (2004) Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 24, 456459.
  • 129
    Fahn S & Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32, 804812.
  • 130
    Chen LJ, Gao YQ, Li XJ, Shen DH & Sun FY (2005) Melatonin protects against MPTP/MPP-induced mitochondrial DNA oxidative damage in vivo and in vitro. J Pineal Res 39, 3442.
  • 131
    Dowling GA, Mastick J, Colling E, Carter JH, Singer CM & Aminoff MJ (2005) Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 6, 459466.
  • 132
    Hill SM, Teplitzky S, Ram PT, Kiefer T, Blask DE, Spriggs LL & Eck KM (1999) Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. Adv Exp Med Biol 460, 345362.
  • 133
    Kiefer T, Ram PT, Yuan L & Hill SM (2002) Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 71, 3745.
  • 134
    Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC & Murphy E (1999) The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 26, 129136.
  • 135
    Kanishi Y, Kobayashi Y, Noda S, Ishizuka B & Saito K (2000) Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 28, 227233.
  • 136
    Hu DN & Roberts JE (1997) Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res 7, 2731.
  • 137
    Hu DN, McCormick SA & Roberts JE (1998) Effects of melatonin, its precursors and derivatives on the growth of cultured human uveal melanoma cells. Melanoma Res 8, 205210.
  • 138
    Gilad E, Laufer M, Matzkin H & Zisapel N (1999) Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 26, 211220.
  • 139
    Anisimov VN, Popovich IG & Zabezhinski MA (1997) Melatonin and colon carcinogenesis. I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18, 15491553.
  • 140
    Anisimov VN, Popovich IG, Shtylik AV, Zabezhinski MA, Ben Huh H, Gurevich P, Berman V, Tendler Y & Zusman I (2000) Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp Toxicol Pathol 52, 7176.
  • 141
    Lissoni P, Chilelli M, Villa S, Cerizza L & Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35, 1215.
  • 142
    Vijayalaxmi Thomas CR Jr, Reiter RJ & Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20, 25752601.
  • 143
    Anisimov VN (2003) Effects of exogenous melatonin – a review. Toxicol Pathol 31, 589603.
  • 144
    Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE & Walborg EF Jr (1998) The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 (Suppl. 1), 289295.
  • 145
    Karbownik M, Lewinski A & Reiter RJ (2001) Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 33, 735753.
  • 146
    Grin W & Grunberger W (1998) A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 45, 6265.
  • 147
    Bartsch C & Bartsch H (1999) Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467, 247264.
  • 148
    Schernhammer ES & Schulmeister K (2004) Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer 90, 941943.
  • 149
    Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA et al. (2005) Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65, 1117411184.
  • 150
    Maestroni GJ, Conti A & Pierpaoli W (1986) Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 13, 1930.
  • 151
    Maestroni GJ (2001) The immunotherapeutic potential of melatonin. Expert Opin Invest Drugs 10, 467476.
  • 152
    Maestroni GJ, Conti A & Lissoni P (1994) Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 54, 47404743.
  • 153
    Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-el-Idrissi M, Sanchez-Margalet V, Goberna R & Guerrero JM (1997) Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 159, 574581.
  • 154
    Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR & Guerrero JM (1999) Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 65, 21432150.
  • 155
    Gonzalez-Haba MG, Garcia-Maurino S, Calvo JR, Goberna R & Guerrero JM (1995) High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J 9, 13311335.
  • 156
    Carrillo-Vico A, Garcia-Perganeda A, Naji L, Calvo JR, Romero MP & Guerrero JM (2003) Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 60, 22722278.
  • 157
    Castrillon PO, Esquifino AI, Varas A, Zapata A, Cutrera RA & Cardinali DP (2000) Effect of melatonin treatment on 24-h variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes. J Neuroendocrinol 12, 758765.
  • 158
    Nunnari G, Nigro L, Palermo F, Leto D, Pomerantz RJ & Cacopardo B (2003) Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels. Infection 31, 379382.
  • 159
    Pandi-Perumal SR, Esquifino AI, Cardinali DP, Miller SC & Maestroni GJM (2006) The role of melatonin in immunoenhancement: Potential application in cancer. Int J Exp Pathol 87, 8187.
  • 160
    Maestroni GJM, Cardinali DP, Esquifino AI & Pandi-Perumal SR (2004) Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol 158, 106111.
  • 161
    Regodon S, Martin-Palomino P, Fernandez-Montesinos R, Herrera JL, Carrascosa-Salmoral MP, Piriz S, Vadillo S, Guerrero JM & Pozo D (2005) The use of melatonin as a vaccine agent. Vaccine 23, 53215327.
  • 162
    Zhdanova IV (2005) Melatonin as a hypnotic: Pro. Sleep Med Rev 9, 5165.
  • 163
    Dijk DJ & Cajochen C (1997) Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 12, 627635.
  • 164
    Zhdanova IV & Tucci V (2003) Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol 5, 225229.
  • 165
    Pandi-Perumal SR, Zisapel N, Srinivasan V & Cardinali DP (2005) Melatonin and sleep in aging population. Exp Gerontol 40, 911925.
  • 166
    Sack RL, Hughes RJ, Edgar DM & Lewy AJ (1997) Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 20, 908915.
  • 167
    Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ & Deng MH (1994) Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 91, 18241828.
  • 168
    Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI & Cardinali DP (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30, 3442.
  • 169
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP & Baker G (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332, 385393.
  • 170
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben Shushan A & Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9, 4150.
  • 171
    Dawson D & Armstrong SM (1996) Chronobiotics – drugs that shift rhythms. Pharmacol Ther 69, 1536.
  • 172
    Arendt J, Bojkowski C, Folkard S, Franey C, Marks V, Minors D, Waterhouse J, Wever RA, Wildgruber C & Wright J (1985) Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp 117, 266283.
  • 173
    Lewy AJ, Ahmed S, Jackson JM & Sack RL (1992) Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 9, 380392.
  • 174
    Arendt J & Skene DJ (2005) Melatonin as a chronobiotic. Sleep Med Rev 9, 2539.
  • 175
    Deacon S & Arendt J (1995) Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res 688, 7785.
  • 176
    Rajaratnam SM, Middleton B, Stone BM, Arendt J & Dijk DJ (2004) Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 561, 339351.
  • 177
    Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK & Reppert SM (1997) Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19, 91102.
  • 178
    Pevet P, Bothorel B, Slotten H & Saboureau M (2002) The chronobiotic properties of melatonin. Cell Tissue Res 309, 183191.
  • 179
    Poirel VJ, Boggio V, Dardente H, Pevet P, Masson-Pevet M & Gauer F (2003) Contrary to other non-photic cues, acute melatonin injection does not induce immediate changes of clock gene mrna expression in the rat suprachiasmatic nuclei. Neuroscience 120, 745755.
  • 180
    Srinivasan V (1997) Melatonin, biological rhythm disorders and phototherapy. Indian J Physiol Pharmacol 41, 309328.
  • 181
    Srinivasan V, Smits G, Kayumov L, Pandi-Perumal SR, Cardinali DP & Thorpy MJ (2006) Melatonin in circadian rhythm sleep disorders. In Neuroendocrine Correlates of Sleep/Wakefulness (CardinaliDP & Pandi-PerumalSR, eds), pp. 269294. Springer, New York.
  • 182
    Burch JB, Yost MG, Johnson W & Allen E (2005) Melatonin, sleep, and shift work adaptation. J Occup Environ Med 47, 893901.
  • 183
    Boivin D (2006) Disturbances of hormonal circadian rhythms in shift workers. In Neuroendocrine Correlates of Sleep/Wakefulness (Cardinali DP & Pandi-Perumal SR, eds), pp. 269294, Springer, New York.
  • 184
    Quera-Salva MA, Guilleminault C, Claustrat B, Defrance R, Gajdos P, McCann CC & De Lattre J (1997) Rapid shift in peak melatonin secretion associated with improved performance in short shift work schedule. Sleep 20, 11451150.
  • 185
    Arendt J (2005) Melatonin in humans: it's about time. J Neuroendocrinol 17, 537538.
  • 186
    Takahashi T, Sasaki M, Itoh H, Ozone M, Yamadera W, Hayshida K, Ushijima S, Matsunaga N, Obuchi K & Sano H (2000) Effect of 3 mg melatonin on jet lag syndrome in an 8-h eastward flight. Psychiatry Clin Neurosci 54, 377378.
  • 187
    Herxheimer A & Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev CD001520.
  • 188
    Cardinali DP, Bortman GP, Liotta G, Perez LS, Albornoz LE, Cutrera RA, Batista J & Ortega GP (2002) A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res 32, 4146.
  • 189
    Cardinali DP, Furio AM, Reyes MP & Brusco LI (2006) The use of chronobiotics in the resynchronization of the sleep/wake cycle. Cancer Causes Control 17, 601609.
  • 190
    Revell VL & Eastman CI (2005) How to trick mother nature into letting you fly around or stay up all night. J Biol Rhythms 20, 353365.
  • 191
    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J & Parkes JD (1991) Delayed sleep phase syndrome response to melatonin. Lancet 337, 11211124.
  • 192
    Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC & van der Meer YG (1998) Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res 7, 135143.
  • 193
    Kayumov L, Brown G, Jindal R, Buttoo K & Shapiro CM (2001) A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med 63, 4048.
  • 194
    Pandi-Perumal SR, Seils LK, Kayumov L, Ralph MR, Lowe A, Moller H & Swaab DF (2002) Senescence, sleep, and circadian rhythms. Ageing Res Rev 1, 559604.
  • 195
    Olde Rikkert MG & Rigaud AS (2001) Melatonin in elderly patients with insomnia. A systematic review. Z Gerontol Geriatr 34, 491497.
  • 196
    Sack RL, Brandes RW, Kendall AR & Lewy AJ (2000) Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 343, 10701077.
  • 197
    Lockley SW, Skene DJ, James K, Thapan K, Wright J & Arendt J (2000) Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 164, R1R6.
  • 198
    Kripke DF, Garfinkel L, Wingard DL, Klauber MR & Marler MR (2002) Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 59, 131136.
  • 199
    Bryant PA, Trinder J & Curtis N (2004) Sick and tired: Does sleep have a vital role in the immune system? Nat Rev Immunol 4, 457467.
  • 200
    Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B & Cardinali DP (2006) Melatonin in mood disorders. World J Biol Psych in press.
  • 201
    Rubin RT, Heist EK, McGeoy SS, Hanada K & Lesser IM (1992) Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry 49, 558567.
  • 202
    Crasson M, Kjiri S, Colin A, Kjiri K, L'Hermite-Baleriaux M, Ansseau M & Legros JJ (2004) Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29, 112.
  • 203
    Beck-Friis J, Kjellman BF, Aperia B, Unden F, von Rosen D, Ljunggren JG & Wetterberg L (1985) Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand 71, 319330.
  • 204
    Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL & Darcourt G (1989) Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 28, 263278.
  • 205
    Mayeda A, Mannon S, Hofstetter J, Adkins M, Baker R, Hu K & Nurnberger JJ (1998) Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res 81, 917.
  • 206
    Weil ZM, Hotchkiss AK, Gatien ML, Pieke-Dahl S & Nelson RJ (2006) Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 68, 425429.
  • 207
    Thompson C, Mezey G, Corn T, Franey C, English J, Arendt J & Checkley SA (1985) The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry 147, 389393.
  • 208
    Venkoba rao A, Parvathi Devi S & Srinivasan V (1983) Urinary melatonin in depression. Indian J Psychiatry 25, 167172.
  • 209
    Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW & Potter WZ (1988) Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 45, 150154.
  • 210
    Dolberg OT, Hirschmann S & Grunhaus L (1998) Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 155, 11191121.
  • 211
    Loo H, Dalery J, Macher JP & Payen A (2002) [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]. Encephale 28, 356362.
  • 212
    Olie P & Emsley R (2005) Confirmed clinical efficacy of agomelatine (25–50 mg) in major depression; two randomized, double-blind controlled studies. Eur Neuropsychopharmacol 15 (Suppl. 3), S416.
  • 213
    Den Boer JA, Bosker FJ & Meesters Y (2006) Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 21 (Suppl. 1), S21S24.
  • 214
    Romijn HJ (1978) The pineal, a tranquillizing organ? Life Sci 23, 22572273.
  • 215
    Massion AO, Teas J, Hebert JR, Wertheimer MD & Kabat-Zinn J (1995) Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med Hypotheses 44, 3946.
  • 216
    Tooley GA, Armstrong SM, Norman TR & Sali A (2000) Acute increases in night-time plasma melatonin levels following a period of meditation. Biol Psychol 53, 6978.
  • 217
    Shapiro CM (1982) Overview: Clinical and physiological comparison of meditation. Am J Psychiatry 139, 267273.
  • 218
    Carlson LE, Speca M, Patel KD & Goodey E (2004) Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29, 448474.
  • 219
    Solberg EE, Holen A, Ekeberg O, Osterud B, Halvorsen R & Sandvik L (2004) The effects of long meditation on plasma melatonin and blood serotonin. Med Sci Monit 10, CR96101.
  • 220
    Raikhlin NT & Kvetnoy IM (1976) Melatonin and enterochromaffine cells. Acta Histochem 55, 1924.
  • 221
    Sjoblom M, Jedstedt G & Flemstrom G (2001) Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest 108, 625633.
  • 222
    Bubenik GA, Ayles HL, Friendship RM, Brown GM & Ball RO (1998) Relationship between melatonin levels in plasma and gastrointestinal tissues and the incidence and severity of gastric ulcers in pigs. J Pineal Res 24, 6266.
  • 223
    Malinovskaya N, Komarov FI, Rapoport SI, Voznesenskaya LA & Wetterberg L (2001) Melatonin production in patients with duodenal ulcer. Neuroendocrinol Lett 22, 109117.
  • 224
    Konturek PC, Konturek SJ, Majka J, Zembala M & Hahn EG (1997) Melatonin affords protection against gastric lesions induced by ischemia-reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol 322, 7377.
  • 225
    Cagnacci A, Arangino S, Angiolucci M, Maschio E & Melis GB (1998) Influences of melatonin administration on the circulation of women. Am J Physiol 274, R335R338.
  • 226
    Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A & Melis GB (1999) Effects of melatonin an vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 83, 1417.
  • 227
    Nishiyama K, Yasue H, Moriyama Y, Tsunoda R, Ogawa H, Yoshimura M & Kugiyama K (2001) Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J 141, E9.
  • 228
    Brugger P, Marktl W & Herold M (1995) Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 345, 1408.
  • 229
    Girotti L, Lago M, Ianovsky O, Carbajales J, Elizari MV, Brusco LI & Cardinali DP (2000) Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 29, 138142.
  • 230
    Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S & Ozbay G (2003) Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 89, 103107.
  • 231
    Girotti L, Lago M, Ianovsky O, Elizari MV, Dini A, Lloret SP, Albornoz LE & Cardinali DP (2003) Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 22, 245248.
  • 232
    Regrigny O, Delagrange P, Scalbert E, Atkinson J & Lartaud-Idjouadiene I (1998) Melatonin improves cerebral circulation security margin in rats. Am J Physiol 275, H139H144.
  • 233
    Scheer FA (2005) Potential use of melatonin as adjunct antihypertensive therapy. Am J Hypertens 18, 16191620.
  • 234
    Hakanson DO & Bergstrom WH (1990) Pineal and adrenal effects on calcium homeostasis in the rat. Pediatr Res 27, 571573.
  • 235
    Roth JA, Kim BG, Lin WL & Cho MI (1999) Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 274, 2204122047.
  • 236
    Nakade O, Koyama H, Ariji H, Yajima A & Kaku T (1999) Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 27, 106110.
  • 237
    Koyama H, Nakade O, Takada Y, Kaku T & Lau KH (2002) Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 17, 12191229.
  • 238
    Ladizesky MG, Cutrera RA, Boggio V, Somoza J, Centrella JM, Mautalen C & Cardinali DP (2001) Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci 70, 557565.
  • 239
    Ostrowska Z, Kos-Kudla B, Marek B, Kajdaniuk D, Staszewicz P, Szapska B & Strzelczyk J (2002) The influence of pinealectomy and melatonin administration on the dynamic pattern of biochemical markers of bone metabolism in experimental osteoporosis in the rat. Neuroendocrinol Lett 23 (Suppl. 1), 104109.
  • 240
    Ostrowska Z, Kos-Kudla B, Marek B & Kajdaniuk D (2003) Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 37, 163174.
  • 241
    Ostrowska Z, Kos-Kudla B, Nowak M, Swietochowska E, Marek B, Gorski J, Kajdaniuk D & Wolkowska K (2003) The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul 37, 211224.
  • 242
    Ladizesky MG, Boggio V, Albornoz LE, Castrillon PO, Mautalen C & Cardinali DP (2003) Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 34, 143151.
  • 243
    Machida M, Miyashita Y, Murai I, Dubousset J, Yamada T & Kimura J (1997) Role of serotonin for scoliotic deformity in pinealectomized chicken. Spine 22, 12971301.
  • 244
    Turgut M, Kaplan S, Turgut AT, Aslan H, Guvenc T, Cullu E & Erdogan S (2005) Morphological, stereological and radiological changes in pinealectomized chicken cervical vertebrae. J Pineal Res 39, 392399.
  • 245
    Fjelldal PG, Grotmol S, Kryvi H, Gjerdet NR, Taranger GL, Hansen T, Porter MJ & Totland GK (2004) Pinealectomy induces malformation of the spine and reduces the mechanical strength of the vertebrae in Atlantic salmon, Salmo salar. J Pineal Res 36, 132139.
  • 246
    Sobajima S, Kin A, Baba I, Kanbara K, Semoto Y & Abe M (2003) Implication for melatonin and its receptor in the spinal deformities of hereditary Lordoscoliotic Rabbits. Spine 28, 554558.
  • 247
    Sadat-Ali M, al Habdan I & al Othman A (2000) Adolescent idiopathic scoliosis. Is low melatonin a cause? Joint Bone Spine 67, 6264.
  • 248
    Dykman TR, Gluck OS, Murphy WA, Hahn TJ & Hahn BH (1985) Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 28, 361368.
  • 249
    Adinoff AD & Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309, 265268.
  • 250
    Lukert BP & Raisz LG (1994) Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 20, 629650.
  • 251
    Weinstein RS (2001) Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2, 6573.
  • 252
    Villareal MS, Klaustermeyer WB, Hahn TJ & Gordon EH (1996) Osteoporosis in steroid-dependent asthma. Ann Allergy Asthma Immunol 76, 369372.
  • 253
    Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M & Ohi H (2000) Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int 66, 195199.
  • 254
    Turner RT, Hannon KS, Greene VS & Bell NH (1995) Prednisone inhibits formation of cortical bone in sham-operated and ovariectomized female rats. Calcif Tissue Int 56, 311315.
  • 255
    King CS, Weir EC, Gundberg CW, Fox J & Insogna KL (1996) Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 59, 184191.
  • 256
    Okazaki Y, Tsurukami H, Nishida S, Okimoto N, Aota S, Takeda S & Nakamura T (1998) Prednisolone prevents decreases in trabecular bone mass and strength by reducing bone resorption and bone formation defect in adjuvant-induced arthritic rats. Bone 23, 353360.
  • 257
    Ladizesky MG, Boggio V, Cutrera RA, Mondelo N, Mastaglia S, Somoza J & Cardinali DP (2006) Melatonin effect on bone metabolism in rats treated with methylprednisolone. J Pineal Res 40, 297304.
  • 258
    Bartness TJ, Demas GE & Song CK (2002) Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp Biol Med (Maywood) 227, 363376.
  • 259
    Iguchi H, Kato KI & Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55, 2729.
  • 260
    Dori D, Casale G, Solerte SB, Fioravanti M, Migliorati G, Cuzzoni G & Ferrari E (1994) Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21, 121126.
  • 261
    Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI & Cardinali DP (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30, 3442.
  • 262
    Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P & Lavie P (2001) Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol Int 18, 513524.
  • 263
    Mishima K, Okawa M, Shimizu T & Hishikawa Y (2001) Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 86, 129134.
  • 264
    Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM & Matsumoto AM (1999) Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 140, 10091012.
  • 265
    Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, Casteilla L & Penicaud L (2003) Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 144, 53475352.
  • 266
    Brydon L, Petit L, Delagrange P, Strosberg AD & Jockers R (2001) Functional expression of mt2 (mel1b) melatonin receptors in human paz6 adipocytes. Endocrinology 142, 42644271.
  • 267
    Rojdmark S, Berg A, Rossner S & Wetterberg L (1991) Nocturnal melatonin secretion in thyroid disease and in obesity. Clin Endocrinol (Oxf) 35, 6165.
  • 268
    Fideleff HL, Boquete H, Fideleff G, Albornoz L, Pérez Lloret S, Suarez M, Esquifino AI, Honfi M & Cardinali DP (2006) Gender-related differences in urinary 6-sulfatoxymelatonin levels in obese pubertal individuals. J Pineal Res 40, 214218.
  • 269
    Glass JD & Knotts LK (1987) A brain site for the antigonadal action of melatonin in the white- footed mouse (Peromyscus leucopus): involvement of the immunoreactive GnRH neuronal system. Neuroendocrinology 46, 4855.
  • 270
    Kennaway DJ & Rowe SA (1995) Melatonin binding sites and their role in seasonal reproduction. J Reprod Fertil Suppl 49, 423435.
  • 271
    Roy D & Belsham DD (2001) Melatonin receptor activation regulates GnRH gene expression and secretion in GT1-7 GnRH neurons: Signal transduction mechanisms. J Biol Chem 277, 251258.
  • 272
    Vanecek J & Klein DC (1992) Melatonin inhibits gonadotropin-releasing hormone-induced elevation of intracellular Ca2+ in neonatal rat pituitary cells. Endocrinology 130, 701707.
  • 273
    Zemkova H & Vanecek J (1997) Inhibitory effect of melatonin on gonadotropin-releasing hormone-induced Ca2+ oscillations in pituitary cells of newborn rats. Neuroendocrinology 65, 276283.
  • 274
    Balik A, Kretschmannova K, Mazna P, Svobodova I & Zemkova H (2004) Melatonin action in neonatal gonadotrophs. Physiol Res 53 (Suppl. 1), S153S166.
  • 275
    Berga SL, Mortola JF & Yen SS (1988) Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 66, 242244.
  • 276
    Soares JM Jr, Masana MI, Ersahin C & Dubocovich ML (2003) Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J Pharmacol Exp Ther 306, 694702.
  • 277
    Frungieri MB, Mayerhofer A, Zitta K, Pignataro OP, Calandra RS & Gonzalez-Calvar SI (2005) Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system. Endocrinology 146, 15411552.
  • 278
    Cardinali DP (1977) Nuclear receptor estrogen complex in the pineal gland. Modulation by sympathetic nerves. Neuroendocrinology 24, 333346.
  • 279
    Vacas MI, Lowenstein PR & Cardinali DP (1979) Characterization of a cytosol progesterone receptor in bovine pineal gland. Neuroendocrinology 29, 8489.
  • 280
    Luboshitzky R, Dharan M, Goldman D, Herer P, Hiss Y & Lavie P (1997) Seasonal variation of gonadotropins and gonadal steroids receptors in the human pineal gland. Brain Res Bull 44, 665670.
  • 281
    Sanchez JJ, Abreu P, Gonzalez-Hernandez T, Hernandez A, Prieto L & Alonso R (2004) Estrogen modulation of adrenoceptor responsiveness in the female rat pineal gland: differential expression of intracellular estrogen receptors. J Pineal Res 37, 2635.
  • 282
    Tamarkin L, Baird CJ & Almeida OF (1985) Melatonin: a coordinating signal for mammalian reproduction? Science 227, 714720.
  • 283
    Reiter RJ (1980) The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1, 109131.
  • 284
    Reiter RJ (1993) The melatonin rhythm: both a clock and a calendar. Experientia 49, 654664.
  • 285
    Karsch FJ, Bittman EL, Foster DL, Goodman RL, Legan SJ & Robinson JE (1984) Neuroendocrine basis of seasonal reproduction. Recent Prog Horm Res 40, 185232.
  • 286
    Malpaux B, Tricoire H, Mailliet F, Daveau A, Migaud M, Skinner DC, Pelletier J & Chemineau P (2002) Melatonin and seasonal reproduction: understanding the neuroendocrine mechanisms using the sheep as a model. Reprod Suppl 59, 167179.
  • 287
    Barrell GK, Thrun LA, Brown ME, Viguie C & Karsch FJ (2000) Importance of photoperiodic signal quality to entrainment of the circannual reproductive rhythm of the Ewe. Biol Reprod 63, 769774.
  • 288
    Kauppila A, Kivela A, Pakarinen A & Vakkuri O (1987) Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity. J Clin Endocrinol Metab 65, 823828.
  • 289
    Aleandri V, Spina V & Morini A (1996) The pineal gland and reproduction. Hum Reprod Update 2, 225235.
  • 290
    Kivela A, Kauppila A, Ylostalo P, Vakkuri O & Leppaluoto J (1988) Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women. Acta Physiol Scand 132, 321327.
  • 291
    Silman R (1991) Melatonin and the human gonadotrophin-releasing hormone pulse generator. J Endocrinol 128, 711.
  • 292
    Waldhauser F, Boepple PA, Schemper M, Mansfield MJ & Crowley WFJ (1991) Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab 73, 793796.
  • 293
    Cohen HN, Hay ID, Annesley TM, Beastall GH, Wallace AM, Spooner R, Thomson JA, Eastwold P & Klee GG (1982) Serum immunoreactive melatonin in boys with delayed puberty. Clin Endocrinol (Oxf) 17, 517521.
  • 294
    Commentz JC & Helmke K (1995) Precocious puberty and decreased melatonin secretion due to a hypothalamic hamartoma. Horm Res 44, 271275.